Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/31955
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mowday, Alexandra M. | - |
dc.contributor.author | Lieuwes, Natasja G. | - |
dc.contributor.author | Biemans, Rianne | - |
dc.contributor.author | Marcus, Damienne | - |
dc.contributor.author | REZAEIFAR, Behzad | - |
dc.contributor.author | RENIERS, Brigitte | - |
dc.contributor.author | Verhaegen, Frank | - |
dc.contributor.author | Theys, Jan | - |
dc.contributor.author | Dubois, Ludwig J. | - |
dc.date.accessioned | 2020-09-23T09:40:49Z | - |
dc.date.available | 2020-09-23T09:40:49Z | - |
dc.date.issued | 2020 | - |
dc.date.submitted | 2020-09-09T13:17:08Z | - |
dc.identifier.citation | CANCERS, 12 (6) , (Art N° 1585) | - |
dc.identifier.uri | http://hdl.handle.net/1942/31955 | - |
dc.description.abstract | Glioblastoma multiforme (GBM) is a common and aggressive malignant brain cancer with a mean survival time of approximately 15 months after initial diagnosis. Currently, the standard-of-care (SOC) treatment for this disease consists of radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ). We sought to develop an orthotopic preclinical model of GBM and to optimize a protocol for non-invasive monitoring of tumor growth, allowing for determination of the efficacy of SOC therapy using a targeted RT strategy combined with TMZ. A strong correlation (r = 0.80) was observed between contrast-enhanced (CE)-CT-based volume quantification and bioluminescent (BLI)-integrated image intensity when monitoring tumor growth, allowing for BLI imaging as a substitute for CE-CT. An optimized parallel-opposed single-angle RT beam plan delivered on average 96% of the expected RT dose (20, 30 or 60 Gy) to the tumor. Normal tissue on the ipsilateral and contralateral sides of the brain were spared 84% and 99% of the expected dose, respectively. An increase in median survival time was demonstrated for all SOC regimens compared to untreated controls (average 5.2 days,p< 0.05), but treatment was not curative, suggesting the need for novel treatment options to increase therapeutic efficacy. | - |
dc.description.sponsorship | KWF KankerbestrijdingKWF Kankerbestrijding [KWF Unieke Kansen #8025]; Special Research Fund (BOF) of Hasselt University and Maastricht University Medical Centre+ | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.rights | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | - |
dc.subject.other | glioblastoma | - |
dc.subject.other | orthotopic models | - |
dc.subject.other | targeted radiotherapy | - |
dc.subject.other | bioluminescence imaging | - |
dc.subject.other | CT imaging | - |
dc.subject.other | temozolomide | - |
dc.subject.other | standard of care | - |
dc.title | Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 6 | - |
dc.identifier.volume | 12 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Dubois, LJ (corresponding author), Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Precis Med, M Lab, NL-6229 ER Maastricht, Netherlands. | - |
dc.description.notes | a.mowday@maastrichtuniversity.nl; n.lieuwes@maastrichtuniversity.nl; | - |
dc.description.notes | rianne.biemans@maastrichtuniversity.nl; | - |
dc.description.notes | d.marcus@maastrichtuniversity.nl; Behzad.Rezaeifar@maastro.nl; | - |
dc.description.notes | brigitte.reniers@uhasselt.be; frank.verhaegen@maastro.nl; | - |
dc.description.notes | jan.theys@maastrichtuniversity.nl; | - |
dc.description.notes | Correspondenceludwig.dubois@maastrichtuniversity.nl | - |
dc.description.other | Dubois, LJ (corresponding author), Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Precis Med, M Lab, NL-6229 ER Maastricht, Netherlands. a.mowday@maastrichtuniversity.nl; n.lieuwes@maastrichtuniversity.nl; rianne.biemans@maastrichtuniversity.nl; d.marcus@maastrichtuniversity.nl; Behzad.Rezaeifar@maastro.nl; brigitte.reniers@uhasselt.be; frank.verhaegen@maastro.nl; jan.theys@maastrichtuniversity.nl; Correspondenceludwig.dubois@maastrichtuniversity.nl | - |
local.publisher.place | ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 1585 | - |
dc.identifier.doi | 10.3390/cancers12061585 | - |
dc.identifier.pmid | 32549357 | - |
dc.identifier.isi | WOS:000549364900001 | - |
dc.contributor.orcid | Mowday, Alexandra/0000-0001-7480-9580; Dubois, | - |
dc.contributor.orcid | Ludwig/0000-0002-8887-4137 | - |
local.provider.type | wosris | - |
local.uhasselt.uhpub | yes | - |
local.description.affiliation | [Mowday, Alexandra M.; Lieuwes, Natasja G.; Biemans, Rianne; Marcus, Damienne; Theys, Jan; Dubois, Ludwig J.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Precis Med, M Lab, NL-6229 ER Maastricht, Netherlands. | - |
local.description.affiliation | [Rezaeifar, Behzad; Verhaegen, Frank] Maastricht Univ, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol Maastro, NL-6229 ER Maastricht, Netherlands. | - |
local.description.affiliation | [Rezaeifar, Behzad; Reniers, Brigitte] Hasselt Univ, Ctr Environm Sci, Res Grp NuTeC, BE-3590 Diepenbeek, Belgium. | - |
item.contributor | Mowday, Alexandra M. | - |
item.contributor | Lieuwes, Natasja G. | - |
item.contributor | Biemans, Rianne | - |
item.contributor | Marcus, Damienne | - |
item.contributor | REZAEIFAR, Behzad | - |
item.contributor | RENIERS, Brigitte | - |
item.contributor | Verhaegen, Frank | - |
item.contributor | Theys, Jan | - |
item.contributor | Dubois, Ludwig J. | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2021 | - |
item.fullcitation | Mowday, Alexandra M.; Lieuwes, Natasja G.; Biemans, Rianne; Marcus, Damienne; REZAEIFAR, Behzad; RENIERS, Brigitte; Verhaegen, Frank; Theys, Jan & Dubois, Ludwig J. (2020) Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide. In: CANCERS, 12 (6) , (Art N° 1585). | - |
item.accessRights | Open Access | - |
crisitem.journal.eissn | 2072-6694 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-12-01585-v2.pdf | Published version | 992.58 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
8
checked on Apr 30, 2024
Page view(s)
60
checked on Aug 15, 2022
Download(s)
14
checked on Aug 15, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.